BioNTech SE (22UA.F)

EUR 107.0

(-2.28%)

Total Debt Summary of BioNTech SE

BioNTech SE's latest annual total debt in 2023 was 219.1 Million EUR , up 3.25% from previous year.
BioNTech SE's latest quarterly total debt in 2024 Q1 was 236.51 Million EUR , up 7.95% from previous quarter.
BioNTech SE reported annual total debt of 212.2 Million EUR in 2022, down -29.62% from previous year.
BioNTech SE reported annual total debt of 301.5 Million EUR in 2021, up 25.53% from previous year.
BioNTech SE reported quarterly total debt of 254.74 Million EUR for 2024 Q2, up 7.71% from previous quarter.
BioNTech SE reported quarterly total debt of 201.9 Million EUR for 2023 Q3, down -1.85% from previous quarter.

Annual Total Debt Chart of BioNTech SE (2023 - 2016)

Historical Annual Total Debt of BioNTech SE (2023 - 2016)

Year	Total Debt	Total Debt Growth
2023	219.1 Million EUR	3.25%
2022	212.2 Million EUR	-29.62%
2021	301.5 Million EUR	25.53%
2020	240.18 Million EUR	248.58%
2019	68.9 Million EUR	27.09%
2018	54.21 Million EUR	7.68%
2017	50.34 Million EUR	88.79%
2016	26.66 Million EUR	0.0%

Year	Total Debt	Total Debt Growth
2024 Q1	236.51 Million EUR	7.95%
2024 Q2	254.74 Million EUR	7.71%
2023 Q3	201.9 Million EUR	-1.85%
2023 FY	219.1 Million EUR	3.25%
2023 Q2	205.7 Million EUR	-1.95%
2023 Q1	209.8 Million EUR	-1.13%
2023 Q4	219.1 Million EUR	8.52%
2022 Q4	212.2 Million EUR	-22.55%
2022 FY	212.2 Million EUR	-29.62%
2022 Q3	274 Million EUR	14.69%
2022 Q2	238.9 Million EUR	28.44%
2022 Q1	186 Million EUR	-38.31%
2021 Q4	301.5 Million EUR	5.16%
2021 Q1	254.6 Million EUR	2684.95%
2021 Q3	286.7 Million EUR	11.64%
2021 Q2	256.8 Million EUR	0.86%
2021 FY	301.5 Million EUR	25.53%
2020 Q3	175.62 Million EUR	149.86%
2020 Q1	66.64 Million EUR	-3.28%
2020 FY	240.18 Million EUR	248.58%
2020 Q4	9.14 Million EUR	-94.79%
2020 Q2	70.28 Million EUR	5.47%
2019 Q1	- EUR	-100.0%
2019 FY	68.9 Million EUR	27.09%
2019 Q4	68.9 Million EUR	1.61%
2019 Q2	61.33 Million EUR	0.0%
2019 Q3	67.81 Million EUR	10.57%
2018 FY	54.21 Million EUR	7.68%
2018 Q4	54.21 Million EUR	0.0%
2018 Q1	- EUR	0.0%
2017 FY	50.34 Million EUR	88.79%
2016 FY	26.66 Million EUR	0.0%

Peer Total Debt Comparison of BioNTech SE

Name	Total Debt	Total Debt Difference
CureVac N.V.	41.85 Million EUR	-423.43%
Biotest Aktiengesellschaft	689.8 Million EUR	68.237%
Biotest Aktiengesellschaft	689.8 Million EUR	68.237%
BRAIN Biotech AG	4.65 Million EUR	-4602.726%
Formycon AG	29.48 Million EUR	-643.065%
Heidelberg Pharma AG	5.83 Million EUR	-3657.259%
Medigene AG	2.95 Million EUR	-7327.119%